Curtiss-Wright: You Can't Buy a Backlog

# Curtiss-Wright: You Can't Buy a Backlog

Curtiss-Wright walked into its Q2 report with a backlog record of $4.5 billion, book-to-bill above 1.2x, raised guidance across the board, and free cash flow up 37%. And what did the market do? It shrugged. The stock fell roughly 3% on the news.

That's the whole story of this trade in one ugly gesture: the results were good, the business is arguably better, and the share price decided it had already been paid for it.

Here's what I actually think happened.

The business is fine. The price is the problem.

Let's give the credit where it's due, because it's real. Q2 sales came in at ~$924 million, up ~5% year-over-year, with operating margins expanding ~110 basis points to 19.4%. Guidance now calls for 8–9% sales growth and diluted EPS of $15.10 to $15.40 — 14 to 16% growth. New orders jumped 8% to ~$1.1 billion. Backlog is a record $4.5 billion. The "Pivot to Growth" thesis that management has been selling isn't vaporware; it's converting into higher-quality earnings in front of our eyes.

Now look at the other side of the tape. The stock is down hard from its highs — my desk has it circling $545 against a peak near $808 — sitting below every moving average on the chart, RSI at 28, which is old-man-oversold but tells you nothing about timing. It had run ~32% year-to-date and ~56% over the trailing year before that correction. That's the reason a beat-and-raise got a shrug: you can't pay top dollar for a company the market already priced as a home run.

The valuation does the heavy lifting. A P/E near 52x and a PEG near 2.5 don't mean the company is broken — they mean the market has bought the idea of the growth and wants execution to arrive on schedule or not at all.

The catch is cadence, and it's a real catch

Here's the part that keeps me up at night, and it's not the valuation.

Earnings at names like this are lumpy. Curtiss-Wright leans hard on a handful of large naval and nuclear programs, and Q2 showed exactly how fragile that can look. Defense Electronics sales actually declined ~3% on order timing despite record orders and a healthy ~28% segment margin — that's a cadence problem, not a demand problem, but the tape doesn't always care which. Ground-defense revenue fell, one source pointing to −8%. Management is openly leaning on a very strong Q4 to hit these record targets.

So the risk isn't "will the backlog fill the pipeline?" The risk is "what if Q4, the quarter everyone is banking on, slips?" A delay in a naval or nuclear program schedules revenue further out, and at 52x earnings, the stock has nowhere to go but down.

There's also the insider tape: 22 sales versus zero purchases over the past six months, including four trades by the Chair & CEO. It's typical after a big run, so don't read too much into it — but when you own a richly valued, lumpy-name stock, you want your owners holding, not cashing.

The nuclear angle is the real optionality

If I had to pick one reason this deserves to trade at a premium, it's nuclear. Curtiss-Wright is moving from design work into actual prototype manufacturing for X-energy's Xe-100 reactor systems — it's becoming a hardware player in the advanced-reactor buildout, not just a consultant to it. Management also flagged the Department of Energy's June conditional $17.5 billion loan commitment toward up to 10 Westinghouse AP1000 reactors, with an expected first AP1000 order landing in 2026.

That's not a tiny tailwind. That's exposure to what may be the most durable industrial buildout of the decade, and Curtiss-Wright has the intellectual property and the facilities (an ~$80 million expansion of its Cheswick, Pennsylvania plant, aimed squarely at naval and commercial-nuclear capacity) to capture it.

My read

Curtiss-Wright is a high-quality business caught in a rich valuation and a genuine technical correction. The fundamentals don't argue with the bull case — record backlog, expanding margins, FCF records, a nuclear option that's actually material. But the tape punished a beat-and-raise, which tells you the market is running out of patience for "eventually good" and wants "good now."

This isn't a chase-from-above situation, and it isn't a fire-sale either. It's a stock where you want to be patient and disciplined: the oversold technicals offer a better entry than the momentum chart, but the pre-earnings timing (Q3 reports around November 4) means you're holding through a binary event with a 52x price tag. That's not a trade to over-size.

The clean version of the thesis? If the backlog and margins keep delivering and the correction holds support, this re-rates on earnings, not on multiple expansion. At current prices you're being paid to wait for the business to prove itself — and you already know how that story usually ends for names trading at 52x. The market doesn't pay premiums for promises it's already heard. It pays them for results it hasn't seen yet.

Curtiss-Wright's delivering results. It just hasn't delivered enough to move the price.